CredoScientia - Bibliothèque

[A 30-year review of gastric cancer surgery: China has achieved leapfrog leadership].

Gastric cancer is one of the most common malignant tumors in China. Over the past 30 years, remarkable progress has been made in the diagnosis and treatment of gastric cancer in China. Especially in t…

Thérapies de Conversion

Liang, H. (2025). [A 30-year review of gastric cancer surgery: China has achieved leapfrog leadership].. Zhonghua Wei Chang Wai Ke Za Zhi, 28(6), 688-692. https://doi.org/10.3760/cma.j.cn441530-20250522-00197

25/06/2025 Lire →

Salvage Pulmonary Resection After Immune Checkpoint or Tyrosine Kinase Inhibitor Therapy for Initially Unresectable Non-Small-Cell Lung Cancer: A Systematic Review.

Systemic conversion of stage III-IV non-small-cell lung cancer (NSCLC) to a surgically resectable state with immune checkpoint inhibitors (ICIs) or tyrosine kinase inhibitors (TKIs) creates an emergi…

Thérapies de Conversion

Gaborean, V., Feier, C. V. I., Vonica, R. C., Faur, A. M., Rus, V. I., & Muntean, C. (2025). Salvage Pulmonary Resection After Immune Checkpoint or Tyrosine Kinase Inhibitor Therapy for Initially Unresectable Non-Small-Cell Lung Cancer: A Systematic Review.. Biomedicines, 13(7). https://doi.org/10.3390/biomedicines13071541

24/06/2025 Lire →

Efficacy of salvage surgery for hepatocellular carcinoma following conversion therapy.

BACKGROUND: Salvage surgery following conversion therapy [transcatheter arterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) and anti-programmed cell death protein 1 (PD-1…

Thérapies de Conversion

Zhang, S. B., Nashan, B., Wang, Y. L., & Zhang, S. G. (2025). Efficacy of salvage surgery for hepatocellular carcinoma following conversion therapy.. World J Clin Oncol, 16(6), 107255. https://doi.org/10.5306/wjco.v16.i6.107255

24/06/2025 Lire →

Efficacy of Hepatic Artery Infusion Chemotherapy with Bevacizumab and Sintilimab in Advanced Hepatocellular Carcinoma: A Case Report.

BACKGROUND Hepatocellular carcinoma (HCC) with vascular invasion at advanced stage is not indicated for surgical options. Conversion therapy is used for unresectable HCC to downstage. Chemotherapy can…

Thérapies de Conversion

Hua, C., Huang, S., Ding, B., Chen, J., & Ding, C. (2025). Efficacy of Hepatic Artery Infusion Chemotherapy with Bevacizumab and Sintilimab in Advanced Hepatocellular Carcinoma: A Case Report.. Am J Case Rep, 26, e947317. https://doi.org/10.12659/AJCR.947317

07/06/2025 Lire →

Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in Asia.

Systemic therapies, primarily cytotoxic chemotherapies, are the mainstay treatment option for pancreatic ductal adenocarcinoma (PDAC) alongside surgery. Several guidelines exist for managing PDAC with…

Thérapies de Conversion

Oh, D. Y., Shen, B., Satoi, S., Zhou, J., Kim, K. P., Choo, S. P., Woo, S. M., Chan, S. L., Shen, L., & Ikeda, M. (2025). Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in Asia.. ESMO Gastrointest Oncol, 8, 100158. https://doi.org/10.1016/j.esmogo.2025.100158

01/06/2025 Lire →

Efficacy analysis of hepatic arterial infusion chemotherapy combined with sintilimab and bevacizumab for initially unresectable hepatocellular carcinoma.

BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) presents a significant challenge in tumor management because of its low resection rates. Conversion therapy aims to transform unresectable tumors in…

Thérapies de Conversion

Chen, Z., Chen, X., Hu, H., Chen, K., Du, C., Xiao, H., & Lan, X. (2025). Efficacy analysis of hepatic arterial infusion chemotherapy combined with sintilimab and bevacizumab for initially unresectable hepatocellular carcinoma.. ILIVER, 4(2), 100163. https://doi.org/10.1016/j.iliver.2025.100163

01/06/2025 Lire →

[Expert consensus on conversion therapy of biliary tract cancer (2025)].

Most patients with biliary tract cancer are diagnosed at advanced stage and lose the opportunity for radical surgery,resulting in dismal prognosis. In recent years,with advances in therapeutic approac…

Thérapies de Conversion

Branch, o. f. . B. i. l. i. a. r. y. . S. u. r. g. e. r. y. ,. C. h. i. n. e. s. e. . S. o. c. i. e. t. y. . o. f. . S. u. r. g. e. r. y. ,. C. h. i. n. e. s. e. . M. e. d. i. c. a. l. . A. s. s. o. c. i. a. t. i. o. n., & Working, G. r. o. u. p. . o. f. . B. i. l. i. a. r. y. . S. u. r. g. e. o. n. s. ,. . C. h. i. n. e. s. e. . C. o. l. l. e. g. e. . o. f. . S. u. r. g. e. o. n. s. ,. . C. h. i. n. e. s. e. . M. e. d. i. c. a. l. . D. o. c. t. o. r. . A. s. s. o. c. i. a. t. i. o. n. (2025). [Expert consensus on conversion therapy of biliary tract cancer (2025)].. Zhonghua Wai Ke Za Zhi, 63(6), 453-460. https://doi.org/10.3760/cma.j.cn112139-20250310-00118

01/06/2025 Lire →

A Survey of Clinical Practices for Hepatocellular Carcinoma Among Experts at Tertiary Hospitals in China From 2020 to 2021.

BACKGROUND: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death in China. The rapid progress in systemic therapies has led to the approval of many therapeutic methods th…

Thérapies de Conversion

Zhao, H., Mao, Y., Wang, H., Zhou, A., Yang, Z., Han, Y., Li, G., Bi, X., Hao, C., Wang, X., Zhou, J., Dai, C., Wen, F., Zhang, J., Liu, R., Li, T., Zhao, L., Niu, Z., Wen, T., … Cai, J. (2025). A Survey of Clinical Practices for Hepatocellular Carcinoma Among Experts at Tertiary Hospitals in China From 2020 to 2021.. Cancer Innov, 4(3), e70006. https://doi.org/10.1002/cai2.70006

01/06/2025 Lire →

Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.

BACKGROUND: Achieving complete response (CR) is a desirable goal in early-to-intermediate-stage hepatocellular carcinoma (HCC). While systemic and locoregional therapies show promise, optimal drug dis…

Thérapies de Conversion

Aoki, T., Kudo, M., Nishida, N., Ueshima, K., Tsuchiya, K., Tada, T., Morita, M., Chishina, H., Takita, M., Hagiwara, S., Ida, H., Minami, Y., Kuroda, H., Nakamura, N., Hiraoka, A., Tomonari, T., Tani, J., Naganuma, A., Kakizaki, S., … Izumi, N. (2025). Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.. J Gastroenterol, 60(6), 738-753. https://doi.org/10.1007/s00535-025-02233-z

01/06/2025 Lire →

Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.

BACKGROUND AND AIMS: The outcome of patients with HCC who achieved complete response (CR) to immune-checkpoint inhibitor (ICI)-based systemic therapies is unclear.APPROACH AND RESULTS: Retrospective s…

Thérapies de Conversion

Scheiner, B., Kang, B., Balcar, L., Radu, I. P., Reiter, F. P., Adžić, G., Guo, J., Gao, X., Yuan, X., Cheng, L., Gorgulho, J., Schultheiss, M., Peeters, F., Hucke, F., Ben, K. h. a. l. e. d. . N., Piseddu, I., Philipp, A., Sinner, F., D'Alessio, A., … Pinter, M. (2025). Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.. Hepatology, 81(6), 1714-1727. https://doi.org/10.1097/HEP.0000000000001163

01/06/2025 Lire →

Navigating the complexities: challenges and opportunities in conversion therapy for advanced hepatocellular carcinoma.

Primary liver cancer ranks as the sixth most prevalent malignant tumor and stands as the second leading cause of cancer-related mortality globally, posing a significant threat to public health. Hepato…

Thérapies de Conversion

Jiang, Y., Dong, X., Zhang, Y., Su, F., Zhao, L., Shi, X., & Zhong, J. (2025). Navigating the complexities: challenges and opportunities in conversion therapy for advanced hepatocellular carcinoma.. Clin Exp Med, 25(1), 169. https://doi.org/10.1007/s10238-025-01698-9

18/05/2025 Lire →

Deep learning progressive distill for predicting clinical response to conversion therapy from preoperative CT images of advanced gastric cancer patients.

Identifying patients suitable for conversion therapy through early non-invasive screening is crucial for tailoring treatment in advanced gastric cancer (AGC). This study aimed to develop and validate …

Thérapies de Conversion

Han, S., Zhang, T., Deng, W., Han, S., Wu, H., Jiang, B., Xie, W., Chen, Y., Deng, T., Wen, X., Liu, N., & Fan, J. (2025). Deep learning progressive distill for predicting clinical response to conversion therapy from preoperative CT images of advanced gastric cancer patients.. Sci Rep, 15(1), 17092. https://doi.org/10.1038/s41598-025-01063-6

16/05/2025 Lire →